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Abstract
Background
Hand, foot, and mouth disease (HFMD) is a common childhood illness caused by serotypes
of the Enterovirus A species in the genus Enterovirus of the Picornaviridae family. The dis-
ease has had a substantial burden throughout East and Southeast Asia over the past 15 y.
China reported 9 million cases of HFMD between 2008 and 2013, with the two serotypes
Enterovirus A71 (EV-A71) and Coxsackievirus A16 (CV-A16) being responsible for the
majority of these cases. Three recent phase 3 clinical trials showed that inactivated mono-
valent EV-A71 vaccines manufactured in China were highly efficacious against HFMD
associated with EV-A71, but offered no protection against HFMD caused by CV-A16. To
better inform vaccination policy, we used mathematical models to evaluate the effect of pro-
spective vaccination against EV-A71-associated HFMD and the potential risk of serotype
replacement by CV-A16. We also extended the model to address the co-circulation,
and implications for vaccination, of additional non-EV-A71, non-CV-A16 serotypes of
enterovirus.
Methods and Findings
Weekly reports of HFMD incidence from 31 provinces in Mainland China from 1 January
2009 to 31 December 2013 were used to fit multi-serotype time series susceptible–
infected–recovered (TSIR) epidemic models. We obtained good model fit for the two-sero-
type TSIR with cross-protection, capturing the seasonality and geographic heterogeneity of
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province-level transmission, with strong correlation between the observed and simulated
epidemic series. The national estimate of the basic reproduction number, R0, weighted by
provincial population size, was 26.63 for EV-A71 (interquartile range [IQR]: 23.14, 30.40)
and 27.13 for CV-A16 (IQR: 23.15, 31.34), with considerable variation between provinces
(however, predictions about the overall impact of vaccination were robust to this variation).
EV-A71 incidence was projected to decreasemonotonically with higher coverage rates of
EV-A71 vaccination. Across provinces, CV-A16 incidence in the post-EV-A71-vaccination
period remained either comparable to or only slightly increased from levels prior to vaccina-
tion. The duration and strength of cross-protection following infection with EV-A71 or CV-A16
was estimated to be 9.95 wk (95% confidence interval [CI]: 3.31, 23.40) in 68% of the popula-
tion (95%CI: 37%, 96%). Our predictions are limited by the necessarily short and under-sam-
pled time series and the possible circulation of unidentified serotypes, but, nonetheless,
sensitivity analyses indicate that our results are robust in predicting that the vaccine should
drastically reduce incidence of EV-A71 without a substantial competitive release of CV-A16.
Conclusions
The ability of our models to capture the observed epidemic cycles suggests that herd immu-
nity is driving the epidemic dynamics caused by the multiple serotypes of enterovirus. Our
results predict that the EV-A71 and CV-A16 serotypes provide a temporary immunizing
effect against each other. Achieving high coverage rates of EV-A71 vaccination would be
necessary to eliminate the ongoing transmission of EV-A71, but serotype replacement by
CV-A16 following EV-A71 vaccination is likely to be transient and minor compared to the
corresponding reduction in the burden of EV-A71-associated HFMD. Therefore, a mass
EV-A71 vaccination program of infants and young children should provide significant bene-
fits in terms of a reduction in overall HFMD burden.
Introduction
Hand, foot, and mouth disease (HFMD) is a common childhood illness caused by serotypes of
the Enterovirus A species in the genus Enterovirus of the Picornaviridae family [1,2]. HFMD
predominantly affects children younger than 5 y of age [3], and most patients exhibit a self-lim-
iting illness that typically includes fever, skin eruptions on the hands and feet, and vesicles in
the mouth. However, a small proportion of infections lead to the development of neurological
and systemic complications that can be fatal, particularly in cases associated with the Enterovi-
rus A71 (EV-A71) serotype [4]. Since 1997, EV-A71-associated HFMD epidemics have been
increasingly reported across the Asia-Pacific region, chronologically in Malaysia [5], Taiwan of
China [6], Japan [7], Singapore [8], Viet Nam [9], Mainland China [10,11], Hong Kong Special
Administrative Region of China [12], South Korea [13], and Cambodia [14]. China reported 9
million cases of HFMD between 2008 and 2013, with the two serotypes EV-A71 and Coxsack-
ievirus A16 (CV-A16) being responsible for 73% of these cases [15]. As such, HFMD is a grow-
ing public health concern that poses a considerable disease burden and economic impact in
affected areas [16,17]. Recent concerns with disease due to outbreaks of Enterovirus D68 in the
US and other countries have only increased the urgency to understand the local viral commu-
nity dynamics of this group of infections [18].
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Transmission of enteroviruses occurs by direct contact with the mucus, saliva, or feces of an
infected individual, or through indirect contact via contaminated surfaces [19]. HFMD infec-
tion characteristically causes acute illness with a duration of approximately 1 wk [20–22].
There are no established antiviral treatments for HFMD, but three recent phase 3 clinical trials
of inactivated monovalent EV-A71 vaccines manufactured in China were found to have high
efficacy (90.0%–97.4%) against EV-A71-associated HFMD in infants and young children [23],
and two of these vaccines were licensed in China in December 2015 [24]. However, these vac-
cines did not offer protection against HFMD caused by the CV-A16 serotype [25].
There is empirical evidence that infection with one serotype of a multi-serotype viral patho-
gen such as influenza or dengue virus can lead to transient immunity against other serotypes of
the same infection [26–28]. There is also some historical and more recent evidence of interfer-
ence between polioviruses (Enterovirus C species) and other enteroviruses [29–31]. For HFMD
specifically, co-infection of a single individual with both serotypes is rarer than expected by
chance [32,33], suggesting the existence of at least short-term cross-protection, and neutraliza-
tion assays have shown partial cross-reactivity between the EV-A71 and CV-A16 serotypes
[34,35], indicating a potential competitive interaction. However, the effects of multi-serotype
interactions remain poorly understood to date. Mathematical models can be used to bridge this
gap, allowing for the estimation of key parameters governing cross-protection and the evalua-
tion of the epidemiological impact of vaccination. Previous modeling studies have used varia-
tions of the continuous-time susceptible–infected–recovered (SIR) model to study the seasonal
patterns of HFMD and its basic and effective reproductive numbers [36–39]. These analyses
have focused on estimating epidemiological parameters of either EV-A71-associated HFMD
alone or all-cause HFMD, and have not accounted for the potential cross-protective effects of
infection with a particular serotype on the dynamics of other serotypes.
To our knowledge, two important aspects of HFMD dynamics are yet to be addressed: first,
the evaluation of the duration and strength of cross-protection between different serotypes
and, second, potential serotype replacement by CV-A16 or other serotypes (e.g., CV-A6 or
CV-A10) following vaccination against EV-A71, due to decreased EV-A71 incidence and an
accompanying reduction in cross-immunity against CV-A16 and other serotypes, as well as
potential increased circulation of these viruses in the population. Such serotype replacement
has been observed, for example, for pneumococcal disease, with increases in the prevalence of
non-vaccine serotypes following use of the pneumococcal heptavalent conjugate vaccine [40–
42]. Vaccination against EV-A71 may potentially have important effects on the burden of
disease caused by CV-A16 and other serotypes, and robust predictions of these effects are nec-
essary before introduction of an EV-A71-containing vaccine into a population.
In this analysis, we adopted a mathematical modeling approach to study the multi-serotype
transmission dynamics of HFMD in the Asia-Pacific region. We linked models closely to sur-
veillance time series, using a multi-serotype time series epidemic model to examine the dynam-
ics of HFMD caused by EV-A71 and CV-A16 in the 31 provinces of Mainland China between
2009 and 2013. We evaluated the potential existence of cross-protection between the two
serotypes and the risk of serotype replacement by CV-A16 following prospective EV-A71 vac-
cination. We also extended the model to assess the co-circulation of additional non-EV-A71,
non-CV-A16 enteroviral serotypes.
Methods
Data
We used three sources of data in this analysis. First, weekly reports of HFMD incidence
between 1 January 2009 and 31 December 2013 (a total of 262 wk) were obtained from a
Modeling Epidemic Dynamics of Enterovirus Serotypes
PLOSMedicine | DOI:10.1371/journal.pmed.1001958 February 16, 2016 3 / 29
national surveillance system maintained by the Chinese Center for Disease Control and Pre-
vention (China CDC) in Beijing, China. These reports were available at two spatial scales: the
seven administrative regions and 31 provinces of China.
Second, we obtained time series of weekly laboratory-confirmed HFMD for a sub-sample of
cases from each province, with virological test results classified as EV-A71, CV-A16, other
non-EV-A71 and non-CV-A16 serotypes of enterovirus, or negative [15]. This information
was aggregated to the regional scale on a monthly basis to reduce potential biases from the
sampling scheme (S1 Fig). The proportions of each serotype were estimated, with all positive
and negative tests included in the denominator. If there were no virological test data available
for a given month, the proportions from the virological tests of the previous month were
substituted. We applied these proportions to the reported case counts from the surveillance
registry to estimate serotype-specific weekly incidence by province (Fig 1; S2 Dataset). Since
infection with EV-A71 or CV-A16 accounted for the majority of total laboratory-confirmed
HFMD cases between 2008 and 2013 (73%), we limited the scope of the main analysis to infec-
tion with either of these two serotypes. We used a time step of 1 wk: the incubation period of
HFMD is 7 to 14 d and viral excretion persists for about 2 wk after symptom onset, so the gen-
eration time would be contained in this time frame. It has previously been shown that the esti-
mation of seasonality is robust to the length of the chosen time step [43].
Third, we obtained yearly birth rates and population sizes between 2009 and 2013 by region
and by province from the National Bureau of Statistics of China (S1 Dataset) [44]. Although
reports of HFMD cases were available from 2008, the time frame of this analysis was limited to
the period between 1 January 2009 and 31 December 2013 because of the sparsity of labora-
tory-confirmed cases during the first year of surveillance.
Host and Transmission Dynamics
The time series susceptible–infected–recovered (TSIR) model is a discrete-time version of the
continuous-time SIR model in which individuals are born and enter the susceptible class of
individuals, become infected and infectious with a disease, and recover and are removed
Fig 1. Weekly reported time series of HFMD cases between 1 January 2009 and 31 December 2013.Weekly reported time series of number of HFMD
cases (y-axis) across time (years 2009–2013, x-axis), aggregated across all 31 provinces of Mainland China, not adjusted for estimated reporting rate and
stratified by serotype: EV-A71 (green), CV-A16 (red), or other non-EV-A71 and non-CV-A16 serotypes of enterovirus (blue).
doi:10.1371/journal.pmed.1001958.g001
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thereafter [45]. Here, we used a multi-serotype extension of the TSIR model that allows for a
cross-protective effect between serotypes [46]. The susceptible compartment of the TSIR
model is defined by:
Stþ1;i ¼ St;i þ Bt  IðrÞt;i =ri  CPt;i ð1Þ
where at each time step t, St,i is the number of individuals that are susceptible to serotype i, Bt is
the number of births (known from demographic data), IðrÞt;i is the reported number of individu-
als infected with serotype i, ρi is the reporting rate of serotype i (assumed to be constant over
the entire time period), and CPt,i represents the effect of cross-protection following infection
with serotype i against all other serotypes. We assumed that there is no maternal immunity
period for HFMD. Assuming that all individuals are born susceptible to HFMD and eventually
become infected, we rearranged Eq 1 as follows:
St;i ¼ Si  N þ D0;i þ
Xt1
k¼0
Bk 
Xt1
k¼0
IðrÞk;i

ri 
Xt1
k¼0
CPk;i ð2Þ
where Si is the mean proportion of individuals that are susceptible to serotype i, N is the mean
number of individuals in the population over the time period of interest, and D0,i is the
unknown deviation around the mean number of individuals in the population that are suscep-
tible to serotype i at the beginning of the time series. We reconstructed the time series of sus-
ceptible individuals by ﬁrst extracting Dt,i, the residuals from the following linear regression:
Xt1
k¼0
Bk ¼
Xt1
k¼0
IðrÞk;i

ri þ
Xt1
k¼0
CPk;i þ Dt;i  D0;i ð3Þ
The ρi values were estimated as the slope of this regression (using the ρj 6¼ i parameters as
iteratively estimated offset terms as per [46], since the It,i and CPt,i terms both depend on ρi)
and are quite low because of the mild nature of the infection [47], though the reporting rates of
EV-A71 are generally higher than those of CV-A16 due to the severity of symptoms. The Dt,i
values were then added to the mean number of susceptible individuals in the population
(Si  N , with Si estimated using marginal proﬁle likelihoods and its 95% conﬁdence interval
[CI] derived from the χ2 distribution with 1 degree of freedom) to yield the complete time
series of susceptible individuals:
St;i ¼ Si  N þ Dt;i ð4Þ
In the multi-serotype TSIR model framework, HFMD transmission is characterized by the
following stochastic frequency-dependent dynamics from the Poisson distribution:
It;i ¼ I
ðrÞ
t;i
.
ri ð5Þ
Itþ1;i  Poisðltþ1;iÞ ð6Þ
E½Itþ1;i ¼ ltþ1;i ¼ bs;i  It;ia  St;i=Nt ð7Þ
where It,i is the number of infected individuals adjusted for reporting rate, λt+1,i is the expected
number of individuals infected with serotype i at time t + 1, βs,i is a seasonally varying transmis-
sion rate, α is a correction parameter accounting for nonseasonal heterogeneities in mixing
[48,49] as well as for time discretization [50], and Nt is the total population size at time t. We
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linearized Eq 7 and estimated βs,i with the following regression model:
logðltþ1;iÞ ¼ logðbs;iÞ þ a  logðIt;iÞ þ logðSt;iÞ  logðNtÞ ð8Þ
Extensive simulation studies indicate that the log-linear model is a better regression model
than the log-transformed linear regression model (S31 and S32 Figs). Additionally, the log-lin-
ear model is a tractable approach to approximating the negative binomial distribution, which is
formally a more satisfying representation of the underlying Reed–Frost epidemic model [51].
Because weekly case counts are relatively high at the province level (and define the over-disper-
sion of the negative binomial distribution), we can closely reflect these dynamics using the log-
linear model and avoid the need to explicitly account for over-dispersion.
Predictions for St+1,i and It+1,i were generated using Eqs 1 and 6, respectively, performing
separate estimation on each of the 31 provinces of China and setting It+1,i = λt+1,i in the deter-
ministic simulations. We used α = 0.95 throughout this analysis for consistency in comparing
seasonal patterns across provinces; a sensitivity analysis varying α values between 0.91 and 0.99
is provided in S22–S30 Figs. Co-infection was omitted from the two-serotype model due to its
relatively rare occurrence in practice (S4 Table). Model fit was assessed by comparing observed
incidence against simulated incidence, and calculating the coefficient of determination (R2)
and absolute yearly prediction error (PE):
PEyear m ¼
X
predicted cases in year m
X
observed cases in year mX
observed cases in year m
 !
 ð9Þ
Cross-Protection, Epidemiological Parameters, and Vaccine Simulation
The multi-serotype TSIR model allows for a cross-protective effect between serotypes. Suppos-
ing that infection with serotype i is fully immunizing against that serotype (e.g., exhibits SIR
epidemic dynamics rather than susceptible–infected–recovered–susceptible [SIRS] epidemic
dynamics) and that a proportion of those infected individuals also gain transient immunity
against all serotypes j 6¼ i, a fixed duration of cross-protection can be modeled as in [46]:
CPt;i ¼ d 
X
j 6¼i
ðIt;j  Itk;jÞ ð10Þ
where δ is the proportion of those infected with one serotype (adjusted for reporting rate) who
are cross-protected against infection from all other serotypes for a ﬁxed duration of k time
steps, and CPt,i represents the effect of cross-protection following infection with serotype i. The
product k  δ represents the average duration of cross-protection, incorporating individuals
who do and do not experience cross-protection [46]. After the speciﬁed length of cross-protec-
tion, we assumed that individuals who had experienced cross-protection subsequently become
re-susceptible to all other serotypes. 95% CIs for k and δ were derived from the proﬁle likeli-
hood using the χ2 distribution with 1 degree of freedom.
We estimated two time-varying epidemiological parameters for each serotype: R0 (basic
reproductive number) and RE (effective reproductive number), obtained by rearranging Eq 7
and defined as:
R0 ¼ bs ð11Þ
RE ¼ Itþ1=It ¼ bs  Ita1  St=Nt ð12Þ
R0 is the average number of secondary infectious persons resulting from one infectious person
following his/her introduction into a completely susceptible population. RE is the average
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number of secondary infectious persons resulting from one infectious person into a population
that is partially immune; it is above 1 when incidence is increasing and below 1 when incidence
is decreasing.
There is an inherent trade-off between having sufficient data to estimate the cross-protec-
tion parameters and having sufficient data to estimate the epidemiological parameters for the
multi-serotype model. We chose to set aside the first year of the full laboratory-confirmed time
series (2009) to back-fit the cross-protection parameters k and δ, and the remaining 4 y of data
(2010–2013) were used for fitting the epidemiological parameters ρi and βs,i. Thus, our estimate
of k was necessarily restricted to be less than 1 y long, and we parsimoniously assumed the val-
ues of k and δ to be the same for infection with any serotype. Log-likelihood surfaces of the
cross-protection parameters were generated by the following modified log-linear regression
model, including the reporting rate as an additional offset term:
logEðIðrÞt;i Þ ¼ logðriÞ þ logðbs;iÞ þ a  logðIt;iÞ þ logðSt;iÞ  logðNtÞ ð13Þ
While our primary model is the two-serotype TSIR model for EV-A71 and CV-A16, we also
explored a three-serotype model including the potential epidemic series encompassing non-
EV-A71, non-CV-A16 serotypes of enterovirus (S6–S8 Tables).
To simulate the effects of introducing monovalent EV-A71 vaccination in the population,
we assumed (based on findings from recent clinical trials) that vaccine-induced immunity
against EV-A71 is narrow and has no immunological effect against CV-A16 infection [52]. In
line with the high efficacy levels found in clinical trials, we also assumed a perfect vaccine effi-
cacy of 100%. To capture the temporal dynamics in the simplest way, seasonality in transmis-
sion was omitted from vaccine simulations [53]. To model the effects of vaccination (assumed
to be administered near birth), the size of each weekly birth cohort was reduced by the vaccine
coverage. For example, if the achieved vaccine coverage was 90%, then 10% of the children
born in a week would be susceptible to HFMD. We also assessed the impact of a broad mono-
valent EV-A71 vaccine that confers the same duration and strength of cross-protection against
CV-A16 as natural infection with EV-A71, as well as the impact of a narrow bivalent EV-A71,
CV-A16 vaccine that is equally protective against the two serotypes. All analysis was conducted
using R version 3.0.2 (http://cran.r-project.org).
Ethical Approval
In May 2008, HFMD was added to the list of notifiable diseases in China. According to China’s
law on the prevention and treatment of infectious diseases, personal identifiers should be col-
lected for individual cases with diagnosis of a notifiable disease, for the purposes of public
health surveillance and response. The National Health and Family Planning Commission of
China decided that the collection of individual data for all notifiable diseases, including
HFMD, according to the national surveillance protocol was part of an ongoing public health
response and was thus exempt from institutional review board assessment.
The China CDC has strict regulations on how to protect patients’ privacy. The National
Center for Public Health Surveillance and Information Services at the China CDC is responsi-
ble for the management of all disease surveillance data, and it anonymized the individual
HFMD data by deleting the personal identifiers (such as patient name, parent name, home
address, and telephone number) before the China CDC co-authors of this article, in the Divi-
sion of Infectious Disease, were given access to the surveillance data for the purposes of
research. The co-authors of this article did not participate in de-identifying the data and do not
have the personal identifiers of the HFMD cases. Data were also aggregated by week, enterovi-
rus serotype, and province by the China CDC co-authors before analysis.
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Results
Model Fit
The two-serotype TSIR model provides a good fit to patterns of HFMD incidence in the 31
Chinese provinces. The median proportion of individuals susceptible (S) to EV-A71 was 0.067
(interquartile range [IQR]: 0.051, 0.153), and the median S for CV-A16 was 0.061 (IQR: 0.051,
0.070); the mean reporting rate of both serotypes (ρ) was approximately 3% (S1 Table). Our
national estimate of R0, weighted by provincial population size, was 26.63 for EV-A71 (IQR:
23.14, 30.40) and 27.13 for CV-A16 (IQR: 23.15, 31.34), with considerable variation between
provinces (Table 1). In comparison with separate one-serotype models (e.g., with no cross-pro-
tection) (S5 Table), the two-serotype model ﬁt as well or better in terms of the mean absolute
yearly PE in 20 of the 31 provinces for EV-A71, and 23 of the 31 provinces for CV-A16
(S7 Table).
In 27 of the 31 provinces, the maximum likelihood estimates from the two-serotype model
indicate the existence of a transient cross-protection between the EV-A71 and CV-A16 sero-
types (Table 2). The population-weighted national average suggests that infection with one
serotype yields k = 9.95 wk (95% CI: 3.31, 23.40) of protection against infection with the other
serotype in δ = 0.68 of the population (95% CI: 0.37, 0.96), resulting in an average duration of
cross-protection of 6.77 wk (95% CI: 2.50, 10.03). We estimated likelihood surfaces of the
cross-protection parameters by province to obtain 95% CIs (S15–S21 Figs).
The two-serotype model performed well in predicting weekly incidence of both EV-A71
and CV-A16 in the representative province of Beijing, capturing both the shape and scale of
incidence from 2010 to 2013 (Fig 2). A sensitivity analysis varying α values in the two-serotype
model for Beijing suggests that 0.95 is a feasible estimate of α (S22–S30 Figs) and that it is able
to capture the yearly epidemic cycles while maintaining spatial stochasticity [54]; the actual
value of α has quantitative implications for the impact of vaccination, though the qualitative
conclusions given below are robust. As α approaches the value of 1, the model behavior
becomes erratic because the underlying Reed–Frost epidemic model is neutrally stable and the
TSIR approximation breaks down [50]. Two-serotype model fits of the observed and simulated
time series for the remaining provinces are provided in S8–S14 Figs.
The time series were too short to do out-of-sample cross-validation, but the robustness of
our inference procedure was tested by stochastically simulating incidence data, fitting the
model, and recovering parameter values. The log-linear regression model recovered more reli-
able estimates of S and βs than the ordinary least squares (OLS) regression model with log-
transformed incidence (S31 and S32 Figs). The estimated S in the OLS regression is biased
high, and the likelihood surface is ﬂattened; the generalized linear models (GLMs) can recover
reliable estimates of S, and the 95% proﬁle likelihood intervals are more reasonable than those
estimated from the OLS regression. The log-linear model was also able to robustly recover
parameter values from simulated data incorporating various levels of cross-protection
(S33 Fig).
Geographic Variations in Transmission
There are two distinct geographic trends of HFMD in China: in the north, there is an annual
peak in incidence in June, and in the south, there are bi-annual peaks in May and in Septem-
ber–October [15]. The models captured these variations and accurately predicted the annual
peaks in incidence in the northern provinces (e.g., Beijing [S11A Fig] and Tianjin [S11B Fig])
and the bi-annual peaks in the southern provinces (e.g., Chongqing [S13A Fig] and Sichuan
[S13B Fig]) for EV-A71 and CV-A16. We also explored the seasonal patterns of RE along a
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latitudinal gradient, which suggest that in the north both serotypes tend to have one period
each year when incidence is increasing and RE is above 1, while in the south there tend to be
two distinct periods within a year during which incidence is increasing in the population
(S3 Fig).
Based on the two-serotype model, we found considerable seasonal and geographic heteroge-
neities in the estimated values of R0 (S2 and S3 Tables). We also disentangled the different
sources of spatial and temporal variation in the transmission rate: within-week variation by
province was estimated by the standard errors of the log(βs) terms from the log-linear
Table 1. Median and interquartile range of R0 by serotype and by province.
Province R0 of EV-A71 (IQR) R0 of CV-A16 (IQR)
Beijing 16.42 (13.68, 18.40) 34.26 (28.54, 37.27)
Tianjin 7.64 (6.60, 9.82) 20.28 (17.70, 26.95)
Hebei 23.67 (20.65, 27.50) 27.31 (23.08, 31.48)
Shanxi 34.96 (28.80, 42.05) 34.91 (28.53, 42.27)
Inner Mongolia 1.61 (1.32, 2.09) 25.13 (19.56, 30.37)
Liaoning 33.76 (27.42, 45.24) 29.67 (23.70, 39.00)
Jilin 3.39 (2.95, 4.36) 38.33 (32.64, 47.55)
Heilongjiang 16.79 (14.68, 22.00) 55.87 (46.21, 70.06)
Shanghai 19.96 (16.34, 22.44) 26.33 (21.92, 29.99)
Jiangsu 26.13 (20.72, 28.41) 30.11 (24.74, 33.17)
Zhejiang 28.33 (23.91, 31.96) 21.80 (18.69, 24.39)
Anhui 27.70 (24.25, 31.45) 22.48 (19.74, 25.70)
Fujian 29.34 (25.87, 32.30) 24.68 (22.09, 27.21)
Jiangxi 19.44 (17.09, 22.25) 16.30 (14.80, 18.37)
Shandong 7.01 (6.01, 8.86) 10.16 (8.72, 12.06)
Henan 9.26 (8.09, 10.18) 25.37 (22.45, 27.72)
Hubei 11.85 (9.84, 13.76) 27.58 (23.44, 31.23)
Hunan 27.56 (23.43, 30.19) 26.68 (22.87, 30.09)
Guangdong 44.91 (40.13, 48.66) 32.31 (27.48, 35.04)
Guangxi 27.21 (24.13, 29.87) 15.87 (14.62, 18.31)
Hainan 11.08 (10.42, 12.45) 21.17 (19.86, 23.53)
Chongqing 80.81 (69.14, 91.82) 22.51 (18.87, 25.49)
Sichuan 41.31 (37.66, 47.22) 38.30 (34.02, 42.82)
Guizhou 26.86 (24.08, 32.46) 24.48 (22.28, 28.61)
Yunnan 61.47 (57.91, 65.91) 26.48 (23.51, 29.16)
Tibet 30.88 (22.85, 38.39) 16.75 (13.19, 23.93)
Shaanxi 53.09 (45.31, 63.09) 40.84 (33.66, 49.20)
Gansu 20.29 (16.08, 24.02) 32.66 (25.79, 42.67)
Qinghai 6.98 (5.18, 9.03) 4.41 (3.18, 5.63)
Ningxia 4.12 (3.09, 4.70) 9.33 (7.67, 11.99)
Xinjiang 4.17 (3.34, 5.43) 24.49 (20.50, 30.63)
National Average 26.63 (23.14, 30.40) 27.13 (23.15, 31.34)
Shown by province and national average, weighted by provincial population size, for EV-A71 and CV-A16 from the two-serotype model with α = 0.95 and
province-speciﬁc maximum likelihood estimates of cross-protection. Point estimate shown is the median b^ s, and the IQR is the 25th and 75th percentiles
of b^ s.
doi:10.1371/journal.pmed.1001958.t001
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regression in Eq 8 and was found to be generally low, between-week variation by province was
assessed by the coefficient of variation in b^s, and between-province variation was found to be
generally high for both EV-A71 and CV-A16 (S1 Table; S2 Fig).
Impact of EV-A71 Vaccination
Using our estimate of R0 of approximately 25 and the basic equation for calculating the critical
vaccination threshold pc = 1 − 1/R0 [55], we estimate that a majority of provinces would require
vaccine coverage levels upwards of 96% of infants and young children to end ongoing trans-
mission of EV-A71-associated HFMD. We simulated the effects of nationally introducing
Table 2. Cross-protection parameter estimates by province.
Province k^ ð95% CIÞ δ^ ð95% CIÞ k^  δ^ ð95% CIÞ
Beijing 21 (9, 25) 1.00 (0.65, 1.00) 21.00 (8.25, 25.00)
Tianjin 22 (2, 31) 1.00 (0.40, 1.00) 22.00 (1.80, 31.00)
Hebei 4 (3, 4) 1.00 (0.80, 1.00) 4.00 (2.85, 3.80)
Shanxi 0 (0, 52) 0.05 (0.00, 1.00) 0.00 (0.00, 5.20)
Inner Mongolia 2 (0, 52) 0.05 (0.00, 1.00) 0.10 (0.00, 33.80)
Liaoning 4 (3, 8) 1.00 (0.70, 1.00) 4.00 (3.00, 8.00)
Jilin 2 (0, 52) 0.95 (0.00, 1.00) 1.90 (0.00, 3.20)
Heilongjiang 52 (0, 52) 0.10 (0.00, 1.00) 5.20 (0.00, 13.00)
Shanghai 9 (6, 18) 1.00 (0.60, 1.00) 9.00 (5.20, 18.00)
Jiangsu 8 (1, 14) 0.40 (0.10, 1.00) 3.20 (0.55, 7.65)
Zhejiang 8 (3, 9) 0.65 (0.40, 1.00) 5.20 (2.55, 8.00)
Anhui 9 (1, 16) 0.30 (0.05, 1.00) 2.70 (0.05, 7.65)
Fujian 6 (3, 8) 1.00 (0.80, 1.00) 6.00 (3.00, 8.00)
Jiangxi 0 (0, 52) 0.05 (0.00, 1.00) 0.00 (0.00, 4.50)
Shandong 4 (3, 7) 1.00 (0.65, 1.00) 4.00 (2.25, 7.00)
Henan 6 (4, 6) 1.00 (0.60, 1.00) 6.00 (3.00, 5.70)
Hubei 2 (0, 52) 1.00 (0.00, 1.00) 2.00 (0.00, 9.00)
Hunan 6 (5, 8) 0.35 (0.15, 0.55) 2.10 (0.90, 3.30)
Guangdong 11 (11, 12) 1.00 (1.00, 1.00) 11.00 (11.00, 12.00)
Guangxi 9 (8, 14) 1.00 (0.95, 1.00) 9.00 (8.00, 14.00)
Hainan 0 (0, 52) 0.05 (0.00, 1.00) 0.00 (0.00, 3.25)
Chongqing 3 (2, 52) 1.00 (0.05, 1.00) 3.00 (1.20, 6.90)
Sichuan 6 (5, 8) 1.00 (0.30, 1.00) 6.00 (1.80, 8.00)
Guizhou 52 (2, 52) 0.15 (0.05, 1.00) 7.80 (1.20, 15.60)
Yunnan 26 (6, 32) 0.20 (0.15, 0.55) 5.20 (2.25, 7.80)
Tibet 3 (2, 31) 1.00 (0.40, 1.00) 3.00 (1.40, 20.15)
Shaanxi 1 (0, 52) 0.75 (0.00, 1.00) 0.75 (0.00, 1.50)
Gansu 0 (0, 52) 0.05 (0.00, 1.00) 0.00 (0.00, 31.20)
Qinghai 26 (0, 52) 0.05 (0.00, 1.00) 1.30 (0.00, 13.75)
Ningxia 4 (1, 29) 0.75 (0.20, 1.00) 3.00 (0.40, 13.05)
Xinjiang 52 (0, 52) 0.15 (0.00, 1.00) 7.80 (0.00, 52.00)
National Average 9.95 (3.31, 23.40) 0.68 (0.37, 0.96) 6.77 (2.50, 10.03)
δ is the proportion of those infected with one serotype who are cross-protected against infection from all other serotypes for a ﬁxed duration of k time
steps, and the product k  δ represents the average duration of cross-protection. 95% CIs for the individual parameters are derived from the proﬁle
likelihood using the χ2 distribution with 1 degree of freedom.
doi:10.1371/journal.pmed.1001958.t002
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three types of EV-A71-containing vaccine on future EV-A71 and CV-A16 incidence (assuming
R0 equals 25 for both serotypes and 90% vaccine coverage at birth as a base case): a broad
monovalent EV-A71 vaccine (kinfection = kvacc = 22 wk and δinfection = δvacc = 1, the highest
province-specific estimates of cross-protection from natural infection), a narrow monovalent
EV-A71 vaccine conferring no cross-protection, and a narrow bivalent EV-A71, CV-A16
vaccine.
Fig 2. Two-serotype TSIRmodel fit for Beijing province. (A and B) Estimated b^ s (y-axis) by week (x-axis) for (A) EV-A71 and (B) CV-A16. (C and D)
Observed number of cases adjusted for reporting rate (y-axis) by week (years 2010–2013, x-axis) (black line) against predictions from 1,000 stochastic
simulations of the entire time series for (C) EV-A71 and (D) CV-A16, showing median value (solid colored line) and 5th and 95th percentiles of the simulations
(shaded area). Calculated with α = 0.95 and province-speciﬁc maximum likelihood estimates of cross-protection (k = 21 wk and δ = 1).
doi:10.1371/journal.pmed.1001958.g002
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For all three vaccines, vaccination provides both a short- and long-term reduction in
national EV-A71 incidence. While EV-A71 vaccination would not affect overall CV-A16 inci-
dence in the long term, we found that a broad monovalent EV-A71 vaccine could cause a tran-
sient benefit in terms of reduced CV-A16 incidence due to cross-protective immunity (Fig 3A).
The transient increase in CV-A16 in the second year following vaccine deployment reflects the
end of a phenomenon known as a “honeymoon period,” during which susceptible individuals
have slowly accumulated.
However, we found from our simulations that a narrow monovalent EV-A71 vaccine could
cause a transient increase in national incidence and lead to a potential competitive release of
CV-A16 (Fig 3B). This increase is due to the reduction in EV-A71 incidence that reduces the
population levels of cross-immunity against CV-A16. The magnitude and duration of this
increase following vaccination will depend on various factors including the achieved EV-A71
vaccine coverage (Fig 3D). Lastly, the deployment of a bivalent vaccine would lead to reduc-
tions in both EV-A71- and CV-A16-associated HFMD (Fig 3C).
Across individual provinces, we found that EV-A71 incidence decreases monotonically with
higher vaccination coverage, and ongoing EV-A71 transmission approaches zero in the range
of the critical vaccination threshold (S5A Fig). We also found that post-vaccination CV-A16
incidence increases slightly or remains comparable to its pre-vaccination levels with use of a
narrow monovalent vaccine, and that the magnitude of this transient increase in CV-A16 inci-
dence scales with EV-A71 vaccine coverage (S5B Fig). Further investigation of other
Fig 3. Simulation of national EV-A71 vaccination and corresponding change in CV-A16 incidence. (A–C) Relative change in incidence of EV-A71
(green) and CV-A16 (red) (y-axis) by year (x-axis) for 10 y following vaccine initiation compared to pre-vaccination equilibria (shown at year 0) in the two-
serotype model, ignoring seasonality in βs. The circles indicate the output from the deterministic simulation, with error bars indicating the 5th and 95th
percentiles of 500 stochastic simulations. Vaccine scenarios explored: (A) broad monovalent EV-A71 vaccine (administered at birth) achieving 90%
coverage, (B) narrow monovalent EV-A71 vaccine achieving 90% coverage, and (C) narrow bivalent EV-A71, CV-A16 vaccine achieving 90% coverage. (D)
Duration and magnitude of change in CV-A16 yearly incidence compared to pre-vaccination equilibria, as a function of narrow monovalent EV-A71 vaccine
coverage (0%, 60%, 70%, 80%, 90%, and 100%). Calculated with α = 0.95 and the highest province-specific maximum likelihood estimates of cross-
protection (kinfection = 22 wk and δinfection = 1).
doi:10.1371/journal.pmed.1001958.g003
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combinations of cross-protection parameters led to the same qualitative conclusions (S6 and
S7 Figs.).
Additional Serotype Circulation
We extended the two-serotype model to address the co-circulation of non-EV-A71, non-
CV-A16 serotypes of enterovirus as an additional third epidemic series, though it is likely to be
a combination of two or more enteroviruses including CV-A6 and CV-A10 [56–58]. In com-
parison with the two-serotype model, the three-serotype model (S6 Table) fit as well or better
in terms of the mean absolute yearly PE in 20 of the 31 provinces for EV-A71, and 22 of the 31
provinces for CV-A16 (S7 Table). We did not see qualitative differences in our results with the
inclusion of this additional serotype epidemic series. Multi-serotype models generate more
multi-collinearity among parameters and introduce statistical identifiability issues, since a
number of parameter value combinations are similarly supported by the likelihood. There is an
inverse relationship between S and b (and therefore incidence) that is mediated by cross-pro-
tection (S4 and S34 Figs). Therefore, we parsimoniously used province-level cross-protection
estimates from the two-serotype model to parametrize the three-serotype model.
Discussion
Findings
The two-serotype TSIR model captured the observed dual epidemic cycles of EV-A71- and
CV-A16-associated HFMD for the 31 provinces in China and the varying seasonal patterns of
transmission in the northern and southern provinces of the country. Comparing values of the
mean absolute yearly PE, we found that the two-serotype model with cross-protection fit the
incidence data better on average than the separate one-serotype models; the public health mes-
sage of HFMD as a highly transmissible infection remained consistent between models. Addi-
tionally, estimates of the cross-protection parameters across provinces suggest that HFMD
serotypes provide a temporary immunizing effect against each other. However, our results sug-
gest considerable geographic variability in this effect, pointing to the substantial value of fur-
ther study. Our estimated national R0 of approximately 25 is consistent with the relatively low
median age at HFMD infection [15], though any loss of immunity (see below) could also keep
the age at primary infection low.
The simulations of EV-A71 vaccination showed that incidence would decrease monotoni-
cally with higher vaccine coverage, and suggest that a mass EV-A71 vaccination program tar-
geted at infants and young children in China could greatly reduce the burden of HFMD caused
by EV-A71. The high R0 values of HFMD serotypes imply that disease elimination is unlikely
and translate to necessary coverage levels of above 96% to achieve population-level immunity.
Additionally, by assuming 100% vaccine efficacy, this estimate of required vaccination coverage
is yet an underestimation. A considerable increase in the prevalence of non-vaccine serotypes
has been observed in other pathogens such as pneumococcal disease [40–42], but our two-sero-
type model results suggest that the incidence of CV-A16 following narrow monovalent
EV-A71 vaccination would be expected to remain comparable to its pre-vaccination levels.
However, a bivalent or polyvalent vaccine would be desirable in light of the co-circulation of
several enteroviruses associated with HFMD [59,60] and because the extent of indirect protec-
tion afforded by vaccination would not be major at these relatively high levels of R0.
This analysis is novel in that it evaluates the existence and magnitude of cross-protection
between different HFMD serotypes in a mathematical modeling context. Our framework
allowed us to look for potential circulating serotype replacement by CV-A16 following
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vaccination against EV-A71. However, further studies are required to better understand the
strength and breadth of immunity conferred by the EV-A71 vaccine relative to the levels of
immunity following natural infection and to test for potential loss of immunity over time.
While we acknowledge that 5 y may be too short a time series to definitively understand sero-
type interactions, based on our findings we are cautiously optimistic that monovalent EV-A71
vaccination is sufficient and will not significantly increase the risk of serotype replacement by
CV-A16 in the population.
Caveats and Directions for Future Work
Using this relatively simple mathematical model, we were able to detect a robust signature of
herd immunity driving the outbreak dynamics of HFMD. Although unlikely to dominate the
observed incidence dynamics, significant evidence for antigenic drift in EV-A71 indicates
some potential loss of immunity, which could affect subsequent immune escape, particularly in
the context of vaccination [61,62]. In general, protection (via a rise in neutralizing antibody
titers) against a wide spectrum of EV-A71 sub-genotypes is observed shortly after vaccination
regardless of whether children already had antibodies [63–65], but longer follow-up is required
to assess whether immunity against the sub-genotypes other than the vaccine serotype wanes
(more rapidly) over time, as seen in influenza and dengue virus. The current time series were
too short to evaluate the extent of loss of immunity following infection (captured, for example,
by SIRS epidemic models [66,67]); however, the quality of the fit underlines that our assump-
tion of strong immunity is reasonable as a first step.
The scope of the data also did not allow us to explicitly disentangle infection with alternative
serotypes such as CV-A6 and CV-A10, which are known to be currently co-circulating in
China and throughout the Asia-Pacific region [68–70] and might show further interactions.
The increasingly multi-collinear nature of cross-protection parameters when additional sero-
types are included in the model poses an analytical challenge. However, if cross-protection
were substantially stronger than our estimates, we might expect to see the epidemics be out of
phase. Understanding the interactions between co-circulating serotypes would allow for more
nuanced estimates of the risk of serotype replacement by non-vaccine serotypes. In this analy-
sis, we assumed stationarity in the mean transmission rate between years because of the short
time series, but there may be confounding effects of year-to-year variation in transmissibility
on estimates of cross-immunity. However, our results are conservative in terms of assessing
potential serotype replacement because such exogenous forcing would increase correlations in
the incidence of different serotypes, which would in turn reduce apparent cross-protection.
Additionally, the absence of age structure in this formulation of the TSIR model did not
allow us to assess the degree of loss of homologous and heterologous immunity over time or
the age-focusing of vaccination. Subsequent models could be further refined to allow for
heterogeneity in mixing and transmission by age, and to model different vaccination imple-
mentation strategies. Furthermore, serological surveys would be useful to better understand
population-level susceptibility to HFMD.
The richness of the spatial scale of these data allow for future work to better understand spa-
tial correlations in incidence and synchrony in the timing of epidemics [71]. These data will
also be useful for evaluating the spatial scale (national, regional, provincial, etc.) at which vacci-
nation efforts should be coordinated and deployed. A better understanding of the dynamics of
serotype invasion and interaction is necessary for accurately predicting the effects of introduc-
ing a new HFMD vaccine formulation with another serotype of enterovirus in China.
Since the recent outbreaks of HFMD have been exclusive to the Asia-Pacific region, it will
also be crucial to understand the potential competitive exclusion and invasion dynamics of
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HFMD and other enteroviral diseases in other parts of the world due to cross-protective immu-
nity from other enteroviruses. Recent concerns with disease due to outbreaks of Enterovirus
D68 in the US and other countries only increase the urgency of understanding the spatial and
viral dynamics of this group of infections. A more accurate reflection of the sero-epidemiologi-
cal and antigenic landscape [72] across HFMD and other enteroviral diseases will be a key
component of efforts to reduce the clinical burden of HFMD and its associated economic costs
in affected areas.
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S1 Chinese Abstract. Chinese translation of the abstract by QL and HY.
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S1 Dataset. Demographic data of China. Province identification number (ID) (for linking to
S2 Dataset), yearly population size (in 10,000s), and yearly crude birth rate (per 1,000) by prov-
ince and national total between 2009 and 2013.
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S2 Dataset. HFMD case data. Estimated weekly case counts of EV-A71, CV-A16, and other
non-EV-A71 and non-CV-A16 serotypes of enterovirus, for each province (linked to S1
Dataset via ID), from 1 January 2009 to 31 December 2013.
(CSV)
S1 Fig. Aggregated proportion of laboratory-confirmed HFMD by serotype. Classified as
proportion of EV-A71 (green), CV-A16 (red), or other non-EV-A71 and non-CV-A16 sero-
types of enterovirus (blue) (y-axis) between 1 January 2009 and 31 December 2013, every 4 wk
(x-axis), on a national scale (A) and by region: east region (B), south region (C), central region
(D), north region (E), northwest region (F), southwest region (G), and northeast region (H).
(TIFF)
S2 Fig. Seasonal heterogeneities in R0. Range in estimated b^s values (y-axis) for each of the 52
wk of the year (x-axis) across all 31 provinces for (A) EV-A71 and (B) CV-A16 in the two-sero-
type model, using province-speciﬁc maximum likelihood estimates of cross-protection. Each
data point represents a province.
(TIFF)
S3 Fig. Seasonal and geographic heterogeneities in RE. Estimated RE values (y-axis) for each
of the 52 wk of the year (x-axis) (each grid cell represents the median value of the 4 y from
2010 to 2013) by province for (A) EV-A71 and (B) CV-A16. Calculated with α = 0.95 and
province-specific maximum likelihood estimates of cross-protection, with provinces ordered
along the latitudinal gradient (north to south).
(TIFF)
S4 Fig. Relationship between epidemiological parameters in Beijing province. Estimated S
(x-axis) against b (y-axis) for (A) EV-A71 and (B) CV-A16 in the two-serotype model for α =
0.95, under varying cross-protection levels (blue–red spectrum, where “None” represents k = 0
wk and δ = 0, and “Max” represents k = 52 wk and δ = 1).
(TIFF)
S5 Fig. Change in EV-A71 and CV-A16 incidence following narrow monovalent EV-A71
vaccination by province. (A) Relative change in yearly incidence of EV-A71 (deterministic
simulation) by province (y-axis) 60 y following vaccine initiation compared to pre-vaccination
equilibria, ignoring seasonality in βs, as a function of narrow EV-A71 vaccine coverage (x-axis).
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Calculated with α = 0.95 and province-specific maximum likelihood estimates of cross-protec-
tion, with provinces ordered by degree of cross-protection (high to low). (B) Maximum tran-
sient increase in yearly incidence of CV-A16 (deterministic simulation) by province (y-axis)
following vaccine initiation compared to pre-vaccination equilibria, ignoring seasonality in βs,
as a function of narrow EV-A71 vaccine coverage (x-axis). Calculated with α = 0.95 and prov-
ince-specific maximum likelihood estimates of cross-protection, with provinces ordered by
degree of cross-protection (high to low). Note that there is no change in the yearly incidence of
CV-A16 after vaccination in provinces where the maximum likelihood estimates of cross-pro-
tection are zero.
(TIFF)
S6 Fig. Simulation of national EV-A71 vaccination and corresponding change in CV-A16
incidence under the upper extreme cross-protection scenario. (A–C) Relative change in inci-
dence of EV-A71 (green) and CV-A16 (red) (y-axis) by year (x-axis) for 10 y following vaccine
initiation compared to pre-vaccination equilibria (at year 0) in the two-serotype model, ignor-
ing seasonality in βs. The circles indicate the output from the deterministic simulation, with
error bars showing the 5th and 95th percentiles of 500 stochastic simulations. Vaccine scenar-
ios explored: (A) broad monovalent EV-A71 vaccine (administered at birth) achieving 90%
coverage, (B) narrow monovalent EV-A71 vaccine achieving 90% coverage, and (C) narrow
bivalent EV-A71, CV-A16 vaccine achieving 90% coverage. (D) Duration and magnitude of
change in CV-A16 yearly incidence compared to pre-vaccination equilibria, as a function of
narrow monovalent EV-A71 vaccine coverage (0%, 60%, 70%, 80%, 90%, and 100%). Calcu-
lated with α = 0.95, kinfection = 52 wk, and δinfection = 1.
(TIF)
S7 Fig. Simulation of national EV-A71 vaccination and corresponding change in CV-A16
incidence under the no cross-protection scenario. (A–C) Relative change in incidence of
EV-A71 (green) and CV-A16 (red) (y-axis) by year (x-axis) for 10 y following vaccine initiation
compared to pre-vaccination equilibria (at year 0) in the two-serotype model, ignoring season-
ality in βs. The circles indicate the output from the deterministic simulation, with error bars
showing the 5th and 95th percentiles of 500 stochastic simulations. Vaccine scenarios explored:
(A) broad monovalent EV-A71 vaccine (administered at birth) achieving 90% coverage, (B)
narrow monovalent EV-A71 vaccine achieving 90% coverage, and (C) narrow bivalent
EV-A71, CV-A16 vaccine achieving 90% coverage. (D) Duration and magnitude of change in
CV-A16 yearly incidence compared to pre-vaccination equilibria, as a function of narrow
monovalent EV-A71 vaccine coverage (same value for all vaccine coverage levels). Calculated
with α = 0.95, kinfection = 0 wk, and δinfection = 0.
(TIF)
S8 Fig. Two-serotype TSIR model fits in the east region. Observed number of cases adjusted
for reporting rate (y-axis) by week (years 2010–2013, x-axis) (black line) against predictions
from 1,000 stochastic simulations of the entire time series for EV-A71 (green) and CV-A16
(red), showing median value (solid colored line) and 5th and 95th percentiles of the simula-
tions (shaded area). Showing individual provinces comprising the east region: (A) Shanghai,
(B) Jiangsu, (C) Zhejiang, (D) Anhui, (E) Fujian, (F) Jiangxi, (G) Shandong. Calculated with α
= 0.95 and province-specific maximum likelihood estimates of cross-protection.
(TIFF)
S9 Fig. Two-serotype TSIR model fits in the south region. Observed number of cases
adjusted for reporting rate (y-axis) by week (years 2010–2013, x-axis) (black line) against pre-
dictions from 1,000 stochastic simulations of the entire time series for EV-A71 (green) and
Modeling Epidemic Dynamics of Enterovirus Serotypes
PLOSMedicine | DOI:10.1371/journal.pmed.1001958 February 16, 2016 16 / 29
CV-A16 (red), showing median value (solid colored line) and 5th and 95th percentiles of the
simulations (shaded area). Showing individual provinces comprising the south region: (A)
Guangdong, (B) Guangxi, (C) Hainan. Calculated with α = 0.95 and province-specific maxi-
mum likelihood estimates of cross-protection.
(TIFF)
S10 Fig. Two-serotype TSIR model fits in the central region. Observed number of cases
adjusted for reporting rate (y-axis) by week (years 2010–2013, x-axis) (black line) against pre-
dictions from 1,000 stochastic simulations of the entire time series for EV-A71 (green) and
CV-A16 (red), showing median value (solid colored line) and 5th and 95th percentiles of the
simulations (shaded area). Showing individual provinces comprising the central region: (A)
Henan, (B) Hubei, (C) Hunan. Calculated with α = 0.95 and province-specific maximum likeli-
hood estimates of cross-protection.
(TIFF)
S11 Fig. Two-serotype TSIR model fits in the north region. Observed number of cases
adjusted for reporting rate (y-axis) by week (years 2010–2013, x-axis) (black line) against pre-
dictions from 1,000 stochastic simulations of the entire time series for EV-A71 (green) and
CV-A16 (red), showing median value (solid colored line) and 5th and 95th percentiles of the
simulations (shaded area). Showing individual provinces comprising the north region: (A) Bei-
jing, (B) Tianjin, (C) Hebei, (D) Shanxi, (E) Inner Mongolia. Calculated with α = 0.95 and
province-specific maximum likelihood estimates of cross-protection.
(TIFF)
S12 Fig. Two-serotype TSIR model fits in the northwest region. Observed number of cases
adjusted for reporting rate (y-axis) by week (years 2010–2013, x-axis) (black line) against pre-
dictions from 1,000 stochastic simulations of the entire time series for EV-A71 (green) and
CV-A16 (red), showing median value (solid colored line) and 5th and 95th percentiles of the
simulations (shaded area). Showing individual provinces comprising the northwest region: (A)
Shaanxi, (B) Gansu, (C) Qinghai, (D) Ningxia, (E) Xinjiang. Calculated with α = 0.95 and prov-
ince-specific maximum likelihood estimates of cross-protection.
(TIFF)
S13 Fig. Two-serotype TSIR model fits in the southwest region. Observed number of cases
adjusted for reporting rate (y-axis) by week (years 2010–2013, x-axis) (black line) against pre-
dictions from 1,000 stochastic simulations of the entire time series for EV-A71 (green) and
CV-A16 (red), showing median value (solid colored line) and 5th and 95th percentiles of the
simulations (shaded area). Showing individual provinces comprising the southwest region: (A)
Chongqing, (B) Sichuan, (C) Guizhou, (D) Yunnan, (E) Tibet. Calculated with α = 0.95 and
province-specific maximum likelihood estimates of cross-protection.
(TIFF)
S14 Fig. Two-serotype TSIR model fits in the northeast region. Observed number of cases
adjusted for reporting rate (y-axis) by week (years 2010–2013, x-axis) (black line) against pre-
dictions from 1,000 stochastic simulations of the entire time series for EV-A71 (green) and
CV-A16 (red), showing median value (solid colored line) and 5th and 95th percentiles of the
simulations (shaded area). Showing individual provinces comprising the northeast region: (A)
Liaoning, (B) Jilin, (C) Heilongjiang. Calculated with α = 0.95 and province-specific maximum
likelihood estimates of cross-protection.
(TIFF)
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S15 Fig. Log-likelihood surfaces of cross-protection parameters in the east region. Esti-
mated log-likelihood values over a range of the cross-protection parameters k, from 0 to 52 (in
weeks; x-axis), and δ, from 0 to 1 (as proportion; y-axis), in the two-serotype model. Calculated
with α = 0.95, showing the maximum likelihood estimate (grid cell with “X”) and 95% confi-
dence region (grid cells with asterisks) in individual provinces comprising the east region: (A)
Shanghai, (B) Jiangsu, (C) Zhejiang, (D) Anhui, (E) Fujian, (F) Jiangxi, (G) Shandong. Grid
cells highlighted pink are where S for either EV-A71 or CV-A16 is estimated to be 100%.
(TIFF)
S16 Fig. Log-likelihood surfaces of cross-protection parameters in the south region. Esti-
mated log-likelihood values over a range of the cross-protection parameters k, from 0 to 52 (in
weeks; x-axis), and δ, from 0 to 1 (as proportion; y-axis), in the two-serotype model. Calculated
with α = 0.95, showing the maximum likelihood estimate (grid cell with “X”) and 95% confi-
dence region (grid cells with asterisks) in individual provinces comprising the south region:
(A) Guangdong, (B) Guangxi, (C) Hainan. Grid cells highlighted pink are where S for either
EV-A71 or CV-A16 is estimated to be 100%.
(TIFF)
S17 Fig. Log-likelihood surfaces of cross-protection parameters in the central region. Esti-
mated log-likelihood values over a range of the cross-protection parameters k, from 0 to 52 (in
weeks; x-axis), and δ, from 0 to 1 (as proportion; y-axis), in the two-serotype model. Calculated
with α = 0.95, showing the maximum likelihood estimate (grid cell with “X”) and 95% confi-
dence region (grid cells with asterisks) in individual provinces comprising the central region:
(A) Henan, (B) Hubei, (C) Hunan. Grid cells highlighted pink are where S for either EV-A71
or CV-A16 is estimated to be 100%.
(TIFF)
S18 Fig. Log-likelihood surfaces of cross-protection parameters in the north region. Esti-
mated log-likelihood values over a range of the cross-protection parameters k, from 0 to 52 (in
weeks; x-axis), and δ, from 0 to 1 (as proportion; y-axis), in the two-serotype model. Calculated
with α = 0.95, showing the maximum likelihood estimate (grid cell with “X”) and 95% confi-
dence region (grid cells with asterisks) in individual provinces comprising the north region:
(A) Beijing, (B) Tianjin, (C) Hebei, (D) Shanxi, (E) Inner Mongolia. Grid cells highlighted pink
are where S for either EV-A71 or CV-A16 is estimated to be 100%.
(TIFF)
S19 Fig. Log-likelihood surfaces of cross-protection parameters in the northwest region.
Estimated log-likelihood values over a range of the cross-protection parameters k, from 0 to 52
(in weeks; x-axis), and δ, from 0 to 1 (as proportion; y-axis), in the two-serotype model. Calcu-
lated with α = 0.95, showing the maximum likelihood estimate (grid cell with “X”) and 95%
confidence region (grid cells with asterisks) in individual provinces comprising the northwest
region: (A) Shaanxi, (B) Gansu, (C) Qinghai, (D) Ningxia, (E) Xinjiang. Grid cells highlighted
pink are where S for either EV-A71 or CV-A16 is estimated to be 100%.
(TIFF)
S20 Fig. Log-likelihood surfaces of cross-protection parameters in the southwest region.
Estimated log-likelihood values over a range of the cross-protection parameters k, from 0 to
52 (in weeks; x-axis), and δ, from 0 to 1 (as proportion; y-axis), in the two-serotype model.
Calculated with α = 0.95, showing the maximum likelihood estimate (grid cell with “X”) and
95% confidence region (grid cells with asterisks) in individual provinces comprising the south-
west region: (A) Chongqing, (B) Sichuan, (C) Guizhou, (D) Yunnan, (E) Tibet. Grid cells
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highlighted pink are where S for either EV-A71 or CV-A16 is estimated to be 100%.
(TIFF)
S21 Fig. Log-likelihood surfaces of cross-protection parameters in the northeast region.
Estimated log-likelihood values over a range of the cross-protection parameters k, from 0 to
52 (in weeks; x-axis), and δ, from 0 to 1 (as proportion; y-axis), in the two-serotype model. Cal-
culated with α = 0.95, showing the maximum likelihood estimate (grid cell with “X”) and 95%
confidence region (grid cells with asterisks) in individual provinces comprising the northeast
region: (A) Liaoning, (B) Jilin, (C) Heilongjiang. Grid cells highlighted pink are where S for
either EV-A71 or CV-A16 is estimated to be 100%.
(TIFF)
S22 Fig. Sensitivity analysis varying α values in the two-serotype TSIR model for Beijing
province: α = 0.91. (A and B) Estimated b^s (y-axis) for (A) EV-A71 and (B) CV-A16 by week
(x-axis). (C and D) Observed number of cases adjusted for reporting rate (y-axis) from 2010 to
2013 (black line) by week (x-axis) against predictions from 1,000 stochastic simulations of the
entire time series for (C) EV-A71 and (D) CV-A16, showing median value (solid colored line)
and 5th and 95th percentiles of the simulations (shaded area). (E and F) Output from deter-
ministic simulation of incidence (y-axis) of (E) EV-A71 and (F) CV-A16 by year (x-axis) for
20 y before to 30 y following vaccine initiation (dotted black line, at year 0), normalized by
serotype-speciﬁc yearly incidence in year −20 and ignoring seasonality in βs. Vaccination
assumed to be narrow monovalent EV-A71 vaccine (administered at birth) achieving 90% cov-
erage. S for EV-A71 = 0.112 and S for CV-A16 = 0.052. Calculated with province-speciﬁc
maximum likelihood estimates of cross-protection (k = 21 wk and δ = 1).
(TIFF)
S23 Fig. Sensitivity analysis varying α values in the two-serotype TSIR model for Beijing
province: α = 0.92. (A and B) Estimated b^s (y-axis) for (A) EV-A71 and (B) CV-A16 by week
(x-axis). (C and D) Observed number of cases adjusted for reporting rate (y-axis) from 2010 to
2013 (black line) by week (x-axis) against predictions from 1,000 stochastic simulations of the
entire time series for (C) EV-A71 and (D) CV-A16, showing median value (solid colored line)
and 5th and 95th percentiles of the simulations (shaded area). (E and F) Output from deter-
ministic simulation of incidence (y-axis) of (E) EV-A71 and (F) CV-A16 by year (x-axis) for 20
y before to 30 y following vaccine initiation (dotted black line, at year 0), normalized by sero-
type-speciﬁc yearly incidence in year −20 and ignoring seasonality in βs. Vaccination assumed
to be narrow monovalent EV-A71 vaccine (administered at birth) achieving 90% coverage. S
for EV-A71 = 0.107 and S for CV-A16 = 0.051. Calculated with province-speciﬁc maximum
likelihood estimates of cross-protection (k = 21 wk and δ = 1).
(TIFF)
S24 Fig. Sensitivity analysis varying α values in the two-serotype TSIR model for Beijing
province: α = 0.93. (A and B) Estimated b^s (y-axis) for (A) EV-A71 and (B) CV-A16 by week
(x-axis). (C and D) Observed number of cases adjusted for reporting rate (y-axis) from 2010 to
2013 (black line) by week (x-axis) against predictions from 1,000 stochastic simulations of the
entire time series for (C) EV-A71 and (D) CV-A16, showing median value (solid colored line)
and 5th and 95th percentiles of the simulations (shaded area). (E and F) Output from deter-
ministic simulation of incidence (y-axis) of (E) EV-A71 and (F) CV-A16 by year (x-axis) for 20
y before to 30 y following vaccine initiation (dotted black line, at year 0), normalized by sero-
type-speciﬁc yearly incidence in year −20 and ignoring seasonality in βs. Vaccination assumed
to be narrow monovalent EV-A71 vaccine (administered at birth) achieving 90% coverage. S
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for EV-A71 = 0.102 and S for CV-A16 = 0.049. Calculated with province-speciﬁc maximum
likelihood estimates of cross-protection (k = 21 wk and δ = 1).
(TIFF)
S25 Fig. Sensitivity analysis varying α values in the two-serotype TSIR model for Beijing
province: α = 0.94. (A and B) Estimated b^s (y-axis) for (A) EV-A71 and (B) CV-A16 by week
(x-axis). (C and D) Observed number of cases adjusted for reporting rate (y-axis) from 2010 to
2013 (black line) by week (x-axis) against predictions from 1,000 stochastic simulations of the
entire time series for (C) EV-A71 and (D) CV-A16, showing median value (solid colored line)
and 5th and 95th percentiles of the simulations (shaded area). (E and F) Output from deter-
ministic simulation of incidence (y-axis) of (E) EV-A71 and (F) CV-A16 by year (x-axis) for
20 y before to 30 y following vaccine initiation (dotted black line, at year 0), normalized by
serotype-speciﬁc yearly incidence in year −20 and ignoring seasonality in βs. Vaccination
assumed to be narrow monovalent EV-A71 vaccine (administered at birth) achieving 90% cov-
erage. S for EV-A71 = 0.098 and S for CV-A16 = 0.047. Calculated with province-speciﬁc
maximum likelihood estimates of cross-protection (k = 21 wk and δ = 1).
(TIFF)
S26 Fig. Sensitivity analysis varying α values in the two-serotype TSIR model for Beijing
province: α = 0.95 (used in main text). (A and B) Estimated b^s (y-axis) for (A) EV-A71 and
(B) CV-A16 by week (x-axis). (C and D) Observed number of cases adjusted for reporting rate
(y-axis) from 2010 to 2013 (black line) by week (x-axis) against predictions from 1,000 stochas-
tic simulations of the entire time series for (C) EV-A71 and (D) CV-A16, showing median
value (solid colored line) and 5th and 95th percentiles of the simulations (shaded area). (E and
F) Output from deterministic simulation of incidence (y-axis) of (E) EV-A71 and (F) CV-A16
by year (x-axis) for 20 y before to 30 y following vaccine initiation (dotted black line, at year 0),
normalized by serotype-speciﬁc yearly incidence in year −20 and ignoring seasonality in βs.
Vaccination assumed to be narrow monovalent EV-A71 vaccine (administered at birth)
achieving 90% coverage. S for EV-A71 = 0.094 and S for CV-A16 = 0.046. Calculated with
province-speciﬁc maximum likelihood estimates of cross-protection (k = 21 wk and δ = 1).
(TIFF)
S27 Fig. Sensitivity analysis varying α values in the two-serotype TSIR model for Beijing
province: α = 0.96. (A and B) Estimated b^s (y-axis) for (A) EV-A71 and (B) CV-A16 by week
(x-axis). (C and D) Observed number of cases adjusted for reporting rate (y-axis) from 2010 to
2013 (black line) by week (x-axis) against predictions from 1,000 stochastic simulations of the
entire time series for (C) EV-A71 and (D) CV-A16, showing median value (solid colored line)
and 5th and 95th percentiles of the simulations (shaded area). (E and F) Output from deter-
ministic simulation of incidence (y-axis) of (E) EV-A71 and (F) CV-A16 by year (x-axis) for
20 y before to 30 y following vaccine initiation (dotted black line, at year 0), normalized by
serotype-speciﬁc yearly incidence in year −20 and ignoring seasonality in βs. Vaccination
assumed to be narrow monovalent EV-A71 vaccine (administered at birth) achieving 90% cov-
erage. S for EV-A71 = 0.091 and S for CV-A16 = 0.045. Calculated with province-speciﬁc
maximum likelihood estimates of cross-protection (k = 21 wk and δ = 1).
(TIFF)
S28 Fig. Sensitivity analysis varying α values in the two-serotype TSIR model for Beijing
province: α = 0.97. (A and B) Estimated b^s (y-axis) for (A) EV-A71 and (B) CV-A16 by week
(x-axis). (C and D) Observed number of cases adjusted for reporting rate (y-axis) from 2010 to
2013 (black line) by week (x-axis) against predictions from 1,000 stochastic simulations of the
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entire time series for (C) EV-A71 and (D) CV-A16, showing median value (solid colored line)
and 5th and 95th percentiles of the simulations (shaded area). (E and F) Output from deter-
ministic simulation of incidence (y-axis) of (E) EV-A71 and (F) CV-A16 by year (x-axis) for
20 y before to 30 y following vaccine initiation (dotted black line, at year 0), normalized by
serotype-speciﬁc yearly incidence in year −20 and ignoring seasonality in βs. Vaccination
assumed to be narrow monovalent EV-A71 vaccine (administered at birth) achieving 90% cov-
erage. S for EV-A71 = 0.087 and S for CV-A16 = 0.044. Calculated with province-speciﬁc
maximum likelihood estimates of cross-protection (k = 21 wk and δ = 1).
(TIFF)
S29 Fig. Sensitivity analysis varying α values in the two-serotype TSIR model for Beijing
province: α = 0.98. (A and B) Estimated b^s (y-axis) for (A) EV-A71 and (B) CV-A16 by week
(x-axis). (C and D) Observed number of cases adjusted for reporting rate (y-axis) from 2010 to
2013 (black line) by week (x-axis) against predictions from 1,000 stochastic simulations of the
entire time series for (C) EV-A71 and (D) CV-A16, showing median value (solid colored line)
and 5th and 95th percentiles of the simulations (shaded area). (E and F) Output from deter-
ministic simulation of incidence (y-axis) of (E) EV-A71 and (F) CV-A16 by year (x-axis) for
20 y before to 30 y following vaccine initiation (dotted black line, at year 0), normalized by
serotype-speciﬁc yearly incidence in year −20 and ignoring seasonality in βs. Vaccination
assumed to be narrow monovalent EV-A71 vaccine (administered at birth) achieving 90% cov-
erage. S for EV-A71 = 0.084 and S for CV-A16 = 0.042. Calculated with province-speciﬁc
maximum likelihood estimates of cross-protection (k = 21 wk and δ = 1).
(TIFF)
S30 Fig. Sensitivity analysis varying α values in the two-serotype TSIR model for Beijing
province: α = 0.99. (A and B) Estimated b^s (y-axis) for (A) EV-A71 and (B) CV-A16 by week
(x-axis). (C and D) Observed number of cases adjusted for reporting rate (y-axis) from 2010 to
2013 (black line) by week (x-axis) against predictions from 1,000 stochastic simulations of the
entire time series for (C) EV-A71 and (D) CV-A16, showing median value (solid colored line)
and 5th and 95th percentiles of the simulations (shaded area). (E and F) Output from deter-
ministic simulation of incidence (y-axis) of (E) EV-A71 and (F) CV-A16 by year (x-axis) for
20 y before to 30 y following vaccine initiation (dotted black line, at year 0), normalized by
serotype-speciﬁc yearly incidence in year −20 and ignoring seasonality in βs. Vaccination
assumed to be narrow monovalent EV-A71 vaccine (administered at birth) achieving 90% cov-
erage. S for EV-A71 = 0.081 and S for CV-A16 = 0.041. Calculated with province-speciﬁc
maximum likelihood estimates of cross-protection (k = 21 wk and δ = 1).
(TIFF)
S31 Fig. Simulated time series for TSIR simulation studies with no cross-protection. Repre-
sentative stochastically simulated, single-serotype 40-y time series data of incidence (y-axis) by
week (x-axis) (S ¼ 0:128) (A) with weekly varying (x-axis), stationary βs (b ¼ 9:407) (y-axis)
(B).
(TIFF)
S32 Fig. Results of TSIR simulation studies with no cross-protection. Calculated with α =
0.95, k = 0 wk, and δ = 0, using data from S31 Fig. (A–C) Estimated βs (y-axis) by week (x-axis)
for this single time series with three regression models: (A) OLS regression with log-trans-
formed data (b estimated to be 3.352), (B) Poisson GLM with log link (b estimated to be
11.224), and (C) quasi-Poisson GLM with log link (b estimated to be 11.122). (D–F) Estimated
S for this single time series (x-axis) and 95% CIs (derived from the proﬁle likelihood [y-axis]
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using the χ2 distribution with 1 degree of freedom) with three regression models: (D) OLS
regression with log-transformed data (0.360, 95% CI: 0.088, 1.000), with negative log-likeli-
hood on the y-axis; (E) Poisson GLM with log link (0.109, 95% CI: 0.095, 0.127), with negative
log-likelihood on the y-axis; and (F) quasi-Poisson GLM with log link (0.109, 95% CI: 0.099,
0.121), with deviance on the y-axis. (G–I) Distribution of recovered S values (x-axis) from
1,000 stochastically simulated time series (S ¼ 0:128 and seasonally varying, stationary βs,
with b ¼ 9:407 as in S31 Fig) with three regression models: (G) OLS regression with log-trans-
formed data, (H) Poisson GLM with log link, and (I) quasi-Poisson GLM with log link. (J–L)
Distribution of recovered b values (x-axis) from 1,000 stochastically simulated time series
(S ¼ 0:128 and seasonally varying, stationary βs, with b ¼ 9:407 as in S31 Fig) with three
regression models: (J) OLS regression with log-transformed data, (K) Poisson GLM with log
link, and (L) quasi-Poisson GLM with log link.
(TIFF)
S33 Fig. Results of TSIR simulation studies with cross-protection. Estimated log-likelihood
values over a range of the cross-protection parameters k, from 0 to 52 (in weeks; x-axis), and δ,
from 0 to 1 (as proportion; y-axis), in the two-serotype model for α = 0.95, showing the maxi-
mum likelihood estimate (grid cell with “X”) and 95% confidence region (grid cells with aster-
isk) for simulated two-serotype data with true cross-protection parameter values of (A) k = 0
wk and δ = 0 (no cross-protection), (B) k = 12 wk and δ = 1, (C) k = 24 wk and δ = 1, and (D)
k = 48 wk and δ = 1.
(TIFF)
S34 Fig. Scatterplot matrix of demographic and epidemiological parameters. Each data
point represents a province; from top left: mean population size from 2009 to 2013, mean
births per week from 2009 to 2013, ratio of total reported EV-A71 cases to total births from
2009 to 2013, ratio of total reported CV-A16 cases to total births from 2009 to 2013, estimated
S for EV-A71 and CV-A16, estimated reporting rate ρ for EV-A71 and CV-A16, and estimated
b for EV-A71 and CV-A16. Calculated with α = 0.95 and the province-speciﬁc maximum like-
lihood estimates of cross-protection, using the two-serotype model.
(TIFF)
S1 Table. Two-serotype TSIR model estimates for EV-A71 and CV-A16.Mean proportion
of individuals that are susceptible to EV-A71 and CV-A16 (S), reporting rate of EV-A71 and
CV-A16 (ρ), mean weekly estimated transmission rate of EV-A71 and CV-A16 (b), and coefﬁ-
cient of variation (CV) in estimated transmission rate of EV-A71 and CV-A16 by province.
Calculated with α = 0.95 and province-speciﬁc maximum likelihood estimates of cross-protec-
tion. The 95% CIs for S are derived from the proﬁle likelihood using the χ2 distribution with
1 degree of freedom; the 95% CIs for ρ are derived from the standard errors for the coefﬁcient
1/ρ in the OLS regression of cumulative births and cumulative cases; the maximum standard
errors (se) of the log(βs) terms across weekly b^s values are from the log-linear regression, repre-
senting variability around estimated βs.
(DOCX)
S2 Table. Spatial and temporal variation in R0 of EV-A71 across provinces. b^s and 95% CIs
on each weekly βs value (row) for EV-A71 for each province (column) from the two-serotype
model with α = 0.95 and province-speciﬁc maximum likelihood estimates of cross-protection.
(DOCX)
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S3 Table. Spatial and temporal variation in R0 of CV-A16 across provinces. b^s and 95% CIs
on each weekly βs value (row) for CV-A16 for each province (column) from the two-serotype
model with α = 0.95 and province-speciﬁc maximum likelihood estimates of cross-protection.
(DOCX)
S4 Table. Omission of co-infection from the two-serotype model.We omit co-infection
from this analysis, as co-infection of a single individual with both serotypes (EV-A71 and
CV-A16) is rarer than expected by chance, given a reasonable sample size of EV-A71 and
CV-A16 infections in a given year. We determined this using data from two published studies
and χ2 tests.
(DOCX)
S5 Table. One-serotype TSIR model estimates for EV-A71 and CV-A16.Mean proportion
of individuals that are susceptible to EV-A71 and CV-A16 (S), reporting rate of EV-A71 and
CV-A16 (ρ), mean weekly estimated transmission rate of EV-A71 and CV-A16 (b), and coefﬁ-
cient of variation (CV) in estimated transmission rate of EV-A71 and CV-A16 by province.
Calculated with α = 0.95. The 95% CIs for S are derived from the proﬁle likelihood using the
χ2 distribution with 1 degree of freedom; the 95% CIs for ρ are derived from the standard errors
for the coefﬁcient 1/ρ in the OLS regression of cumulative births and cumulative cases; the
maximum standard errors (se) of the log(βs) terms across weekly b^s values are from the log-lin-
ear regression, representing variability around estimated βs.
(DOCX)
S6 Table. Three-serotype TSIR model estimates for EV-A71 and CV-A16.Mean proportion
of individuals that are susceptible to EV-A71 and CV-A16 (S), reporting rate of EV-A71 and
CV-A16 (ρ), mean weekly estimated transmission rate of EV-A71 and CV-A16 (b), and coefﬁ-
cient of variation (CV) in estimated transmission rate of EV-A71 and CV-A16 by province.
Calculated with α = 0.95 and province-speciﬁc maximum likelihood estimates of cross-protec-
tion from the two-serotype model. The 95% CIs for S are derived from the proﬁle likelihood
using the χ2 distribution with 1 degree of freedom; the 95% CIs for ρ are derived from the stan-
dard errors for the coefﬁcient 1/ρ in the OLS regression of cumulative births and cumulative
cases; the maximum standard errors (se) of the log(βs) terms across weekly b^s values are from
the log-linear regression, representing variability around estimated βs.
(DOCX)
S7 Table. Within-province estimates of mean absolute yearly prediction error between
observed and simulated weekly incidence. Shown for both EV-A71 and CV-A16 from 2010
to 2013, for the one-, two-, and three-serotype models with α = 0.95 and province-specific
maximum likelihood estimates of cross-protection from the two-serotype model. Values with
asterisks indicate lower PE for the serotype in the two-serotype model compared to the one-
serotype model, and values with carets indicate lower PE for the serotype in the three-serotype
model compared to the two-serotype model.
(DOCX)
S8 Table. Within-province estimates of the coefficient of determination (R2) between
observed and simulated weekly incidence. Shown for both EV-A71 and CV-A16 from 2010
to 2013, for the one-, two-, and three-serotype models with α = 0.95 and province-specific
maximum likelihood estimates of cross-protection from the two-serotype model.
(DOCX)
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Editors' Summary
Background
Hand, foot, and mouth disease (HFMD)—a common ailment that mainly affects young
children—is caused by a group of enteroviruses (Enterovirus A species), which are close
relatives of polioviruses (Enterovirus C species). Enteroviruses are divided into various
viral serotypes (variants defined by molecules on their surface that are recognized by the
immune system), and the most common serotypes that cause HFMD are Enterovirus A71
(EV-A71) and Coxsackievirus A16 (CV-A16). Enteroviruses spread from person to person
through contact with the mucus or saliva produced when an infected individual coughs or
sneezes, with the feces or the fluid from vesicles of an infected individual, and through
contact with contaminated surfaces. Frequent handwashing and good hygiene practices
can reduce the spread of HFMD. Symptoms of HFMD include fever, sore throat, a non-
itchy red rash with small blisters on the hands and feet, and painful mouth ulcers. HFMD
is usually a self-limiting illness, and most children recover within 7–10 days. A small pro-
portion of patients infected with EV-A71 develop severe complications such as meningitis
(infection of the membranes around the brain and spinal cord) or encephalitis (infection
of the brain). Currently, there is no specific treatment for HFMD, and vaccines are not yet
available for routine use.
WhyWas This Study Done?
HFMD is increasingly common in East and Southeast Asia. China, for example, reported 9
million cases of HFMD between 2008 and 2013. Vaccination is a specific and effective way
to reduce the burden of HFMD in China. In three clinical trials, inactivated monovalent
EV-A71 vaccines made in China were highly efficacious against EV-A71-associated
HFMD but provided no protection against CV-A16-associated HFMD (an inactivated
monovalent vaccine contains a single virus strain that is unable to replicate; exposure to
the vaccine “primes” the immune system to respond quickly when challenged with live
virus, thereby preventing infection with that virus). So, before these vaccines can be used
for routine vaccination of infants, it is important to know whether vaccination with EV-
A71 will alter the burden of HFMD caused by other enterovirus serotypes. In particular, it
is important to know whether infection with EV-A71 provides cross-protection against
CV-A16 and whether infections with CV-A16 or other serotypes might increase following
vaccination against EV-A71 because of increased circulation of these viruses in the popula-
tion (serotype replacement). Here, the researchers use mathematical models to assess the
effect of vaccination against EV-A71-associated HFMD in China and the potential risk of
serotype replacement by CV-A16.
What Did the Researchers Do and Find?
The researchers used weekly data on HFMD incidence collected in 31 Chinese provinces
between 2009 and 2013 to develop a two-serotype time series susceptible–infected–recov-
ered epidemic model (a model in which individuals are born, become susceptible to a dis-
ease, become infected and infectious with the disease, and recover). The model accurately
simulated the epidemic cycles of EV-A71- and CV-A16-associated HFMD for the 31 prov-
inces and the seasonal transmission patterns in both northern and southern Chinese prov-
inces. It provided an estimate of cross-protection following infection with EV-A71 or CV-
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A16 of ten weeks in 68% of the population (an average duration of cross-protection of 6.77
weeks). The estimated basic reproduction number (the average number of additional cases
one case of an infectious disease generates in an otherwise uninfected population) across
China for both serotypes was 25, which means that vaccination coverage levels of above
96% are required to achieve population-level immunity. Finally, the model predicted a
decrease in EV-A71-associated HFMD incidence with higher rates of EV-A71 vaccination
and suggested that CV-A16 incidence following EV-A71 vaccination would be comparable
to or only slightly higher than its incidence before vaccination.
What Do These Findings Mean?
These findings suggest that herd immunity (indirect protection from infectious disease
that occurs when most of a population has become immune to an infection, thereby pro-
viding some protection for the rare individuals who are not immune) is driving the
dynamics of the HFMD epidemic caused by multiple enterovirus serotypes in China.
Moreover, they suggest that the infection with EV-A71 or CV-A16 serotype can provide
temporary immunity against each the other serotype and that serotype replacement by
CV-A16 following EV-A71 vaccination is likely to be transient and minor compared to
the reduction in the burden of EV-A71-associated HFMD produced by vaccination. The
accuracy of these findings depends on the assumptions included in the model and the
quality and quantity of data used to run the models. However, the researchers suggest that
a mass EV-A71 vaccination campaign targeted at infants and young children should
greatly reduce the burden of HFMD in China, provided a high vaccination uptake level is
achieved.
Additional Information
This list of resources contains links that can be accessed when viewing the PDF on a device
or via the online version of the article at http://dx.doi.org/10.1371/journal.pmed.1001958.
• The US Centers for Disease Control and Prevention provide information on hand, foot,
and mouth disease (in English and Spanish), including a podcast on the condition
• The UK National Health Service Choices website provides detailed information on
hand, foot, and mouth disease
• Further information about hand, foot, and mouth disease is provided by the World
Health Organization (including up-to-date HFMD surveillance reports from China), the
Nemours Foundation (in English and Spanish), and MedlinePlus (in English and
Spanish)
• The Government of the Hong Kong Special Administrative Region Department of
Health Centre for Health Protection provides information on hand, foot, and mouth
disease
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